Aditxt Inc. (ADTX)
0.14
-0.02 (-10.20%)
At close: Jan 14, 2025, 3:59 PM
0.12
-8.22%
Pre-market Jan 15, 2025, 06:36 AM EST
undefined% (undefined)
| Bid | 0.12 |
| Market Cap | 1.92M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 628.8 |
| PE Ratio (ttm) | 0 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 0.12 |
| Volume | 17,867,262 |
| Avg. Volume (20D) | 6,489,672 |
| Open | 0.14 |
| Previous Close | 0.16 |
| Day's Range | 0.13 - 0.14 |
| 52-Week Range | 0.13 - 218.00 |
| Beta | undefined |
About ADTX
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body natural...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 30, 2020
Employees 47
Stock Exchange NASDAQ
Ticker Symbol ADTX
Website https://www.aditxt.com
Analyst Forecast
According to 1 analyst ratings, the average rating for ADTX stock is "Buy." The 12-month stock price forecast is $undefined, which is a decrease of NaN% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
3 months ago ·
Source
-25.63%
Aditxt shares are trading lower after the company ...
Unlock content with
Pro Subscription
3 months ago ·
Source
-15.89%
Aditxt shares are trading lower after its acquisition target Evofem Biosciences filed a preliminary proxy for the stockholder approval of the deal.
